Right to FDA-Approved Medicines Act
- Sponsor
- Rep. Ross, Deborah K. [D-NC-2]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jul 17, 2025
Bottom line
This bill aims to federally protect access to all FDA-approved medicines and the ability of healthcare providers to offer them, overriding conflicting state or federal restrictions.
What it actually does
This bill establishes a federal statutory right for individuals to obtain FDA-approved medicines and for healthcare providers to provide such medicines, free from government coercion. It broadly preempts conflicting state and federal laws, with specific exceptions for federal health care coverage provisions, and includes robust enforcement mechanisms.
Proponents argue
Proponents argue that the bill ensures consistent access to safe and effective medications across the country, preventing states from interfering with medical decisions made between patients and their healthcare providers regarding FDA-approved treatments. They emphasize patient autonomy and provider freedom as essential components of healthcare access.
Opponents contend
Opponents might contend that the bill oversteps federal authority by broadly preempting state laws, potentially undermining states' rights to regulate healthcare within their borders. They may also raise concerns about the bill's explicit override of the Religious Freedom Restoration Act and its broad scope, which could impact various state-level public health policies.
The bill is concise and can be read quickly, allowing for a relatively fast assessment of its core intent and potential impacts.
Section 4(a)
Establishment of Statutory Right to FDA-Approved Medicines
This section creates a federal statutory right for individuals to obtain FDA-approved medicines without coercion and for healthcare providers to offer these medicines, along with related information, referrals, and services. It aims to protect both patient access and provider autonomy regarding federally approved medications, ensuring a baseline level of access nationwide.
Supporters argue
Supporters argue this provision is crucial for safeguarding patient health by ensuring that medical decisions, particularly concerning FDA-approved treatments, are not unduly restricted by state or local governments. It empowers healthcare providers to practice medicine without political interference.
Critics contend
Critics might argue that this provision represents an overreach of federal power into areas traditionally regulated by states, potentially limiting states' abilities to respond to local public health concerns or to regulate medical practice within their jurisdictions.
Tradeoffs
This provision balances federal authority in drug approval with state regulatory powers over healthcare practice and public health. It prioritizes uniform access to FDA-approved medicines over varied state-level restrictions.
Section 4(b) and 4(c)
Prohibition on Restrictive Limitations and Exception Clause
This provision prohibits any limitation or requirement that singles out FDA-approved medicines or providers/facilities offering them, and impedes access. An exception allows such a limitation only if the party establishes, by clear and convincing evidence, that it significantly advances access to FDA-approved medicines and is the least restrictive alternative. This sets a high bar for any government attempting to restrict access.
Section 5(a) and 5(b)
Supremacy over Federal and State Law
This section establishes that the Act supersedes and applies to all federal and state laws, whether statutory or common law, adopted before or after its enactment. It explicitly states that neither federal nor state governments may prohibit or restrict the sale, provision, or use of FDA-approved medicines, or aid in obtaining them. It also clarifies that the Act applies notwithstanding the Religious Freedom Restoration Act of 1993.
Section 5(c)
Non-Supersession of Federal Health Care Coverage Laws
This subsection clarifies that the Act does not supersede or affect federal laws related to health care coverage, including group health plans, health insurance, or federal health care programs like Medicaid and the Affordable Care Act's preventive services mandate. It explicitly states the Act does not require the provision of specific benefits under these programs.
Section 7
Enforcement Mechanisms
This section grants the Attorney General the authority to initiate civil actions against states or government officials who violate the Act. It also establishes a private right of action, allowing any individual or entity (including health care providers or patients) adversely affected by a violation to sue. Courts are empowered to award equitable relief (like injunctions) and mandate costs and reasonable attorney's fees to prevailing plaintiffs. It also abrogates state immunity.
This subsection expands the definition of 'government official' for the purposes of this Act to include 'any individual who, by operation of a provision of Federal or State law, is permitted to implement or enforce a limitation or requirement that violates section 4'.
Section 6(c)
Why it matters:This is a technical expansion of a definition, which is common in legislative drafting. However, its placement might make it less obvious that it broadens the scope of who can be sued under the Act beyond traditional government employees.
Case for: Supporters would argue this ensures that individuals or entities deputized by state law to enforce restrictions on FDA-approved medicines cannot evade accountability by claiming they are not direct government employees. It closes a potential loophole for enforcement.
Case against: Critics might argue this provision could extend liability to private citizens or entities who are merely following state law, potentially chilling legitimate actions or creating an overly broad class of defendants.
Estimated impact: Potentially significant, as it expands the pool of individuals and entities who could be subject to civil action under the Act, increasing the deterrent effect against state-level restrictions.